サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1636336

ファブリー病市場レポート：タイプ別、診断・治療別、エンドユーザー別、地域別、2025-2033年

Fabry Disease Market Report by Type (Type 1, Type 2, and Others), Diagnosis and Treatment (Diagnosis, Treatment), End User (Hospitals, Homecare, Specialty Clinics, and Others), and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 130 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
ファブリー病市場レポート：タイプ別、診断・治療別、エンドユーザー別、地域別、2025-2033年
出版日: 2025年01月10日
発行: IMARC
ページ情報: 英文 130 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

ファブリー病市場の世界市場規模は2024年に21億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに37億米ドルに達し、2025年から2033年にかけて6.02%の成長率（CAGR）を示すと予測しています。ファブリー病に罹患する患者数の増加と、遺伝子治療や酵素補充療法などの効果的な新規治療に対するニーズの高まりが、市場を牽引する主な要因のひとつです。

ファブリー病（αガラクトシダーゼA欠損症）は、重度のx連鎖性リソソーム遺伝性疾患であり、油、脂肪酸、ワックスなど様々な脂質貯蔵成分や脂肪様成分の代謝に必要な酵素の欠乏によって引き起こされます。診断されないまま、あるいは治療されないまま放置されると、血管や組織の詰まり、進行性の腎不全、神経障害、さらには脳卒中を引き起こす可能性があります。現在、ファブリー病は酵素補充療法（ERT）と補助療法によって治療することができます。これとは別に、腎臓や心臓の問題の発生を抑制するために、遺伝子検査、血液検査、非経口検査によってさらに診断することができます。これらのアプローチにより、第一および第二レベルの合併症の発症リスクを予防し、根本的な酵素欠乏症を改善することができます。その結果、病院や専門クリニックでは、ファブリー病のタイムリーな診断と効果的な治療のために、さまざまな方法が広く活用されています。

ファブリー病市場傾向：

ファブリー病に罹患する患者数の増加と、罹患者を安定させるための遺伝子治療、酵素補充基質減少治療、シャペロン治療などの精密かつ効果的な治療に対するニーズの高まりが、主に市場成長の原動力となっています。これに伴い、疾患治療のための経口投与薬やカプセルの需要が高まっていることも、成長を促す要因となっています。さらに、画期的な疾患治療オプションを設計するためにヘルスケア部門に投資する規制機関によって行われている有利なイニシアチブは、市場の成長を支えています。さらに、ファブリー病の診断と治療のための遠隔医療ソリューションや在宅ケア環境の導入など、著しい技術進歩が市場成長を後押ししています。また、ファブリー病に関する意識の高まりも市場を大きく牽引しています。医師や個人の間で、早期診断や複数の予防策が利用可能であるという意識が高まっており、これが市場成長に寄与しています。あらゆる種類の慢性疾患にかかりやすい老年人口が着実に増加していることも、市場成長に寄与している要因です。その他の要因としては、医療インフラの大幅な改善、遺伝性疾患治療の進歩に向けた重点的な取り組み強化、治療・投薬ポートフォリオの拡充に向けた継続的な研究開発活動などが挙げられ、市場の明るい見通しを生み出しています。

本レポートで扱う主な質問

  • 世界のファブリー病市場はこれまでどのように推移し、今後どのように推移するのか？
  • ファブリー病市場の世界市場における促進要因、抑制要因、機会は何か？
  • 主要な地域市場とは？
  • 最も魅力的なファブリー病市場はどの国か？
  • タイプ別の市場内訳は？
  • 診断・治療に基づく市場内訳は？
  • エンドユーザー別の市場内訳は？
  • 世界のファブリー病市場の競合構造は？
  • ファブリー病市場の世界市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のファブリー病市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • タイプ1
    • 市場動向
    • 市場予測
  • タイプ2
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 市場内訳：診断・治療別

  • 診断
    • 市場動向
    • 主要セグメント
      • 血液検査
      • 遺伝子検査
      • 非経口検査
      • その他
    • 市場予測
  • 治療
    • 市場動向
    • 主要セグメント
      • 酵素補充療法
      • 経口療法
      • 補助療法
      • その他
    • 市場予測

第8章 市場内訳：エンドユーザー別

  • 病院
    • 市場動向
    • 市場予測
  • 在宅ケア
    • 市場動向
    • 市場予測
  • 専門クリニック
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ

第10章 促進要因・抑制要因・機会

  • 概要
  • 促進要因
  • 抑制要因
  • 機会

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amicus Therapeutics
    • Freeline
    • Idorsia Pharmaceuticals Ltd
    • JCR Pharmaceuticals Co. Ltd
    • Protalix BioTherapeutics
    • Sangamo Therapeutics Inc.
図表

List of Figures

  • Figure 1: Global: Fabry Disease Market: Major Drivers and Challenges
  • Figure 2: Global: Fabry Disease Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Fabry Disease Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Fabry Disease Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Fabry Disease Market: Breakup by Diagnosis & Treatment (in %), 2024
  • Figure 6: Global: Fabry Disease Market: Breakup by End User (in %), 2024
  • Figure 7: Global: Fabry Disease Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Fabry Disease (Type 1) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Fabry Disease (Type 1) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Fabry Disease (Type 2) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Fabry Disease (Type 2) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Fabry Disease (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Fabry Disease (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Fabry Disease (Diagnosis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Fabry Disease (Diagnosis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Fabry Disease (Treatment) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Fabry Disease (Treatment) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Fabry Disease (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Fabry Disease (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Fabry Disease (Homecare) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Fabry Disease (Homecare) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Fabry Disease (Specialty Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Fabry Disease (Specialty Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Fabry Disease (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Fabry Disease (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Fabry Disease Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Fabry Disease Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Fabry Disease Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Fabry Disease Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Fabry Disease Industry: Value Chain Analysis
  • Figure 77: Global: Fabry Disease Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Fabry Disease Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Fabry Disease Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Fabry Disease Market Forecast: Breakup by Diagnosis & Treatment (in Million USD), 2025-2033
  • Table 4: Global: Fabry Disease Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Fabry Disease Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Fabry Disease Market: Competitive Structure
  • Table 7: Global: Fabry Disease Market: Key Players
目次
Product Code: SR112025A6668

The global fabry disease market size reached USD 2.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.02% during 2025-2033. The increasing number of patients suffering from fabry disease and the escalating need for effective novel therapies, such as genetic and enzyme replacement therapy, represent some of the key factors driving the market.

Fabry disease, or alpha galactosidase-A deficiency, represents a severe x-linked lysosomal inherited disorder that is caused by the lack of enzymes that are required to metabolize various lipid storage and fat-like components, including oils, fatty acids, and waxes. If left undiagnosed or untreated, it might result in clogging of blood vessels and tissue, progressive kidney failures, nerve damage, and even strokes. Currently, fabry disease can be treated with the support of enzyme replacement therapies (ERT) and adjunct therapy. Apart from this, it can be further diagnosed through genetic, blood, and parenteral examinations to inhibit the occurrence of kidney and heart problems. These approaches prevent the risk of developing first and second-level complications and correct underlying enzyme deficiency. Consequently, hospitals and specialty clinics widely utilize various procedures for the timely diagnosis and effective treatment of the Fabry disease.

Fabry Disease Market Trends:

The increasing number of patients suffering from fabry disease and the escalating need for precise and effective therapies, such as genetic, enzyme replacement substrate reduction, and chaperone treatments to stabilize individuals from suffering disease, are primarily driving the market growth. In line with this, the rising demand for orally administered medications and capsule for disease treatment is acting as another growth-inducing factor. Additionally, the favorable initiatives being undertaken by regulatory bodies to invest in the healthcare sector for the designing of breakthrough disease treatment options are supporting the market growth. Moreover, significant technological advancements, such as the introduction of telemedicine solutions and home care settings for the diagnosis and treatment of Fabry disease, are favoring the market growth. The market is also significantly driven by the rising awareness regarding the disease. There is an increasing consciousness regarding the availability of early-stage diagnosis and multiple preventive measures amongst physicians and individuals, which is contributing to the market growth. The steadily increasing geriatric population, which is susceptible to any kind of chronic ailments, is another factor contributing to the market growth. Other factors, such as significant improvements in the healthcare infrastructure, an enhanced focus on the advancement of the genetic disease therapies, and continuous research and development (R&D) activities to expand treatment and medication portfolios, are creating a positive outlook for the market.

Key Market Segmentation:

Type Insights:

  • Type 1
  • Type 2
  • Others
  • The report has also provided a detailed breakup and analysis of the fabry disease market based on the type. This includes Type 1, Type 2 and others.

Diagnosis and Treatment Insights:

  • Diagnosis
  • Blood Test
  • Genetic Test
  • Parenteral Test
  • Others
  • Treatment
  • Enzyme Replacement Therapy
  • Oral Therapy
  • Adjunct Therapy
  • Others

End User Insights:

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Regional Insights:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa
  • The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for Fabry disease. Some of the factors driving the North America fabry disease market included the increasing prevalence of fabry disease and the ongoing approvals of advanced therapeutics by regional governments for the disorder treatment.

Competitive Landscape:

  • The report has also provided a comprehensive analysis of the competitive landscape in the global fabry disease market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Amicus Therapeutics, Freeline, Idorsia Pharmaceuticals Ltd, JCR Pharmaceuticals Co. Ltd, Protalix BioTherapeutics, Sangamo Therapeutics Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

  • How has the global fabry disease market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global fabry disease market?
  • What are the key regional markets?
  • Which countries represent the most attractive fabry disease markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the diagnosis and treatment?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global fabry disease market?
  • Who are the key players/companies in the global fabry disease market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Fabry Disease Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Type 1
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Type 2
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Diagnosis & Treatment

  • 7.1 Diagnosis
    • 7.1.1 Market Trends
    • 7.1.2 Key Segments
      • 7.1.2.1 Blood Test
      • 7.1.2.2 Genetic Test
      • 7.1.2.3 Parenteral Test
      • 7.1.2.4 Others
    • 7.1.3 Market Forecast
  • 7.2 Treatment
    • 7.2.1 Market Trends
    • 7.2.2 Key Segments
      • 7.2.2.1 Enzyme Replacement Therapy
      • 7.2.2.2 Oral Therapy
      • 7.2.2.3 Adjunct Therapy
      • 7.2.2.4 Others
    • 7.2.3 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Homecare
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Specialty Clinics
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Amicus Therapeutics
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Freeline
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Idorsia Pharmaceuticals Ltd
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
    • 14.3.4 JCR Pharmaceuticals Co. Ltd
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
      • 14.3.4.4 SWOT Analysis
    • 14.3.5 Protalix BioTherapeutics
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Sangamo Therapeutics Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.